PARD (Poniard Pharmaceuticals) Shareholder Yield % : 0.00% (As of Sep. 2011)

Poniard Pharmaceuticals  (OTCPK:PARD) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.

Poniard Pharmaceuticals Shareholder Yield % Related Terms

The historical data trend for Poniard Pharmaceuticals's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Shareholder Yield % Chart

Poniard Pharmaceuticals Annual Data
	Trend	Dec01	Dec02	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10
Shareholder Yield %		Get a 7-Day Free Trial					0.00	0.00	0.00	0.00	0.00

Poniard Pharmaceuticals Quarterly Data
	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11
Shareholder Yield %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

PARD vs OBMP, NSPX, ATRX: Shareholder Yield % Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Shareholder Yield % falls into.

Poniard Pharmaceuticals Shareholder Yield % Calculation

Poniard Pharmaceuticals's Shareholder Yield % for the quarter that ended in Sep. 2011 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Poniard Pharmaceuticals Business Description